Virtu Financial’s Royalty Pharma RPRX Stock Holding History

Virtu Financial’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450K	Buy	+8,022	New	+$418K	0.01%	571
2025 Q2	–	Sell	-25,830	Closed	-$804K	–	1969
2025 Q1	$804K	Buy	25,830 +7,510	+41%	+$238K	0.04%	348
2024 Q4	$467K	Buy	+18,320	New	+$486K	0.02%	528
2024 Q1	–	Sell	-13,888	Closed	-$390K	–	1993
2023 Q4	$390K	Buy	13,888 +4,611	+50%	+$127K	0.03%	488
2023 Q3	$252K	Sell	9,277 -17,359	-65%	-$516K	0.03%	577
2023 Q2	$819K	Buy	+26,636	New	+$902K	0.06%	263
2023 Q1	–	Sell	-7,604	Closed	-$300K	–	2020
2022 Q4	$300K	Buy	7,604 +417	+6%	+$17.4K	0.04%	495
2022 Q3	$289K	Buy	+7,187	New	+$307K	0.03%	669
2021 Q4	–	Sell	-9,833	Closed	-$355K	–	2112
2021 Q3	$355K	Sell	9,833 -13,994	-59%	-$544K	0.03%	630
2021 Q2	$977K	Buy	+23,827	New	+$1.01M	0.09%	213
2020 Q3	–	Sell	-6,299	Closed	-$306K	–	1447
2020 Q2	$306K	Buy	+6,299	New	+$312K	0.04%	539

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's RPRX Position: Q2 2026 in Review

Virtu Financial opened a new position in Royalty Pharma (RPRX) in Q2 2026: 8,022 shares worth $450K. The stake represents 0.01% of the portfolio and ranks #571 among its holdings. This is a return to the name: Virtu Financial previously reported a position in RPRX as recently as Q1 2025.

Virtu Financial first reported a position in RPRX in Q2 2020 and has held it in 11 quarters since. The position peaked at $977K in Q2 2021. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Virtu Financial held 8,022 shares of Royalty Pharma worth $450K as of Q2 2026.
Royalty Pharma was a new Virtu Financial position in Q2 2026.
Royalty Pharma made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #571 holding.
Virtu Financial first reported a position in Royalty Pharma in Q2 2020 and has held it in 11 quarters since.
Virtu Financial's Royalty Pharma position peaked at $977K in Q2 2021.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.